$BLUE Unusual #darkpool activity ~ 2.48 million shares at $8.01 ~ 80% of 30D Avg Vol 🍋22% Short/82 mil flt🍋 $GERN Another bio seeing unusual DP - 3.03 million shares at $3.30 ~ 25% of 30D Avg Vol https://t.co/5DuagXdx48

#gern $gern https://t.co/w9UXJH0VTI

$GERN - Geron's Data Allows Development Of Several Catalysts. https://t.co/Cm98YlGFV2 #finance #investing #economy

I’ll be honest the $gern move today other than the pre funded warrants of course was a bit of a head scratcher. Data horrid, offering was at $2.45 and it ran to $3…odd

$OCGN DONT chase the great news. They will just naked short it down later always the same pattern ALSO like $GERN watch for the quick 2ndary. They naked short into the great news FRAUD ST Plus the warrants https://t.co/Z9TebBUVST

DEMO - $GERN Trying to have no excuses not to stay active in the market. I've put way to much heart and soul into this to fade away because of delayed funding. Wishing everyone the best this year!! https://t.co/1b9HGSnv9U

Apparently Adam F, some barely institutional family office types, and some low IQ ppl really hate the $GERN data. Data were overall better than expected and post-ESA/luspatercept transfusion dependent LR/intermediate MDS is a real mkt, likely >$1bn

$GERN is moving. Waiting for another breakout. https://t.co/PSkXsrqino

$GERN - Geron: The First Success Story Of The New Year. https://t.co/if2mihKBVA #stockmarket #trading #finance

Wtf is $GERN

$GERN -no gap stats, no baggies -high IO of 50% -active warrants, s3 for 175m, atm for 79m @FlashSec #DayTrading https://t.co/0UpeJ3OjHU

When you have a big short trying everything to cover. Fake news!! $gern

Geron $GERN, biotech that once sparked talk of immortality, finally gets a (more modest) success https://t.co/63IGrnDFk5 via @Jasonmmast

$GERN it's been a long journey since 2018 let the results be good 🤞🤞🤞🤞

$GERN all comes down to tomorrow. Either $0 or $6 by EOD.

$GERN we are now at 3 sticks https://t.co/FsKGlZc5oJ

$GERN (+15% AH) Ph 3 Data Tomorrow AM 🗞️ IMerge Phase 3 trial • imetelstat [GRN163L] (telomerase inhibitor) • Lower risk myelodysplastic syndromes (MDS) Will host a conference call to discuss top-line results 8:00 a.m. ET.

$GERN Announces Conference Call for Top-Line Results from IMerge Phase 3 January 4. Buckle up folks https://t.co/28TDrnBmKA

Biotech Stock News 1/3 @ close 📰 $AUPH 38% Patent settled $ASLN 21% Partners w/ $TMO $ATNX 18% CMC issues $TXMD 12% License out $HCM 11% Ph3 enroll $GERN 4% Ph 3 data 2moro $PDSB -20% License w/ $MRK $PHAT -20% CRL?? $VERA -64% Ph 2 data $TLSA $NRXP https://t.co/ljHWxXI3tN

$GERN Ph3 IMerge in MDS tomorrow morning https://t.co/GVTtpTsCVz

$GERN https://t.co/XX5CGlKLWG